Insulin therapy in type 2 diabetes

被引：0
作者：
Liebl A. [1 ,2 ]
机构：
[1] Diabetes- und Stoffwechselzentrum, Fachklinik Bad Heilbrunn
[2] Diabetes- und Stoffwechselzentrum, Fachklinik Bad Heilbrunn, 83670 Bad Heilbrunn
来源：
Der Diabetologe | 2007年 / 3卷 / 3期
关键词：
Insulin; Insulin analogue; Prandial insulin therapy; Premixed insulin; Type; 2; diabetes;
D O I：
10.1007/s11428-007-0132-4
中图分类号：
学科分类号：
摘要：
Basal insulin in combination with oral antidiabetic agents primarily reduces fasting blood glucose and is a simple starter therapy with limited long-term success. As an alternative, premixed insulins reduce fasting as well as postprandial blood glucose, which is of importance concerning pathophysiology and the development of late diabetes complications. The therapeutic results with analogue premixed insulins show superiority to basal insulin only, and intensification with premixed analogues is easily achievable. Nevertheless, there is lack of flexibility in daily life. Prandial insulin therapy in combination with nocturnal basal insulin tries to restore normal physiology and offers the best therapeutic results and flexibility when performed professionally. Compared with conventional insulins, short- and long-acting insulin analogues can lead to improved blood glucose levels and safety and are more patient-friendly. For all therapies, simple treatment algorithms are available. © Springer Medizin Verlag 2007.
引用
收藏
页码：221 / 232
页数：11
相关论文
共 15 条
  • [1] Bergenstal R.M., Johnson M.L., Powers M.A., Et al., Using a simple algorithm (ALG) to adjust mealtime glulisine (GLU) based on pre-prandial glucose patterns is a safe and effective alternative to carbohydrate counting, Diabetes Care, 55, (2006)
  • [2] Garber A.J., Premixed insulin analogues for the treatment of diabetes mellitus, Drugs, 66, pp. 31-49, (2006)
  • [3] Garber A.J., Wahlen J., Wahl T., Et al., Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1 -2-3 study), Diabetes Obes Metab, 8, pp. 58-66, (2006)
  • [4] Goudswaard A.N., Furlong N.J., Rutten G.E., Et al., Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus, Cochrane Database Syst Rev, (2004)
  • [5] Heise T., Nosek L., Ronn B.B., Et al., Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes, Diabetes, 53, pp. 1614-1620, (2004)
  • [6] Hermansen K., Davies M., Derezinski T., Et al., A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucoselowering drugs in insulin-naive people with type 2 diabetes, Diabetes Care, 29, pp. 1269-1274, (2006)
  • [7] Kahn S.E., Haffner S.M., Heise M.A., Et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy, N Engl J Med, 355, pp. 2427-2443, (2006)
  • [8] Klein O., Lynge J., Endahl L., Et al., Insulin detemir and insulin glargine: Similar time-action profiles in subjects with type 2 diabetes, Diabetes Care, 55, (2006)
  • [9] Kurtzhals P., Schaffer L., Sorensen A., Et al., Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use, Diabetes, 49, pp. 999-1005, (2000)
  • [10] Liebl A., Prager R., Kaiser M., Et al., Biphasic insulin aspart 30 (BIAsp 30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach HbA1c target: The PREFER Study, Diabetes, 55, (2006)
12